<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813655</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0429</org_study_id>
    <secondary_id>2015-003357-17</secondary_id>
    <nct_id>NCT02813655</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)</brief_title>
  <acronym>ESYBRECHE</acronym>
  <official_title>Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of Synacthène® versus placebo in
      the treatment of post-dural puncture syndrome in patients receiving epidural analgesia,
      spinal analgesia, or combined spinal-epidural analgesia for labour.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of blood patch use</measure>
    <time_frame>Day 15</time_frame>
    <description>Assessment of the rate of blood patch use between experimental group (Synacthène®) and control group between day 0 and day 15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Day 15</time_frame>
    <description>Type, severity and number of side effects in each group (control and experimental) between day 0 and day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of headache</measure>
    <time_frame>Day 15</time_frame>
    <description>Duration of headache in each group (control and experimental) between day 0 and day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of headache</measure>
    <time_frame>Day 15</time_frame>
    <description>Intensity of headache in each group (control and experimental) between day 0 and day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgesic use (type and duration) in each group (control and experimental)</measure>
    <time_frame>Day 15</time_frame>
    <description>analgesic use (type and duration) in each group (control and experimental) between day 0 and day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-patch number</measure>
    <time_frame>Day 15</time_frame>
    <description>blood-patch number per patient in each group (control and experimental) between day 0 and day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first analgesic use after injection of treatment (Synacthène® or placebo)</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Post-dural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetracosactide (Synacthène®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo saline (0.9% NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracosactide (Synacthène®)</intervention_name>
    <description>Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.
All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo saline (0.9% NaCl)</intervention_name>
    <description>placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.
All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All women who received epidural, spinal, or combined spinal-epidural labour analgesia and
        presenting post-dural puncture headache:

          -  Intense: with ≥3 / 10 numerical rating pain scale

          -  Appearing within 5 days after delivery

          -  Aggravating in sitting or standing position and / or improving supine

          -  Can be associated with one of the following criteria: tinnitus, nausea, photophobia,
             neck stiffness or pain, hearing loss

          -  After exclusion of clinically differential diagnoses (preeclampsia or eclampsia,
             cerebral venous thrombosis, migraine)

          -  Age greater than or equal to 18 years

          -  Affiliation to social security scheme

          -  Inform Consent signed after oral and written information

        Exclusion Criteria:

          -  Presence of diplopia (indication of immediate blood patch)

          -  Contraindication to ACTH or Synacthène® (unbalanced hypertension, uncontrolled
             diabetes, uncontrolled psychosis, infectious viral disease state or evolving)

          -  Processing of Torsade de Pointe provider (astenizole, bepridil, erythromycin IV,
             halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine)

          -  Live vaccine in the months prior to inclusion

          -  Hypersensitivity to Synacthène®

          -  Patient who have previously received Synacthène® after delivery

          -  Contraindication to blood patch (fever or leukocytosis, HIV or HCV patient)

          -  Eclampsia or preeclampsia during this pregnancy

          -  Patient who have received prophylactic blood patch (at diagnosis of Accidental Dural
             Puncture)

          -  Minor under 18 or protected

          -  Psychological disorders do not allowing informed consent

          -  Refusal of participation in the study or participation in another ongoing
             interventional study

          -  Withdrawal of consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nadia STEER, MD</last_name>
    <phone>+ 33 4 26 10 92 55</phone>
    <email>nadia.steer@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle DELFOUR</last_name>
    <phone>+33 4 26 73 27 25</phone>
    <email>isabelle.delfour@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon / hôpital de la Croix rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia STEER, MD</last_name>
      <phone>+ 33 4 26 10 92 55</phone>
      <email>nadia.steer@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle DELFOUR</last_name>
      <phone>+33 4 26 73 27 25</phone>
      <email>isabelle.delfour@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tetracosactide</keyword>
  <keyword>Synacthène®</keyword>
  <keyword>cosyntropin</keyword>
  <keyword>post-dural syndrom</keyword>
  <keyword>post-dural puncture headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

